التفاصيل البيبلوغرافية
| العنوان: |
Feasibility, safety, and efficacy of early prophylactic donor lymphocyte infusion after T cell-depleted allogeneic stem cell transplantation in acute leukemia patients |
| المؤلفون: |
van der Zouwen, Boris, Koster, E. A. S., von dem Borne, P. A., Oosten, L. E. M., Roza-Scholten, M. W. I., Snijders, T. J. F., van Lammeren, D., van Balen, P., Marijt, W. A. F., Veelken, H., Falkenburg, J. H. F., de Wreede, L. C., Halkes, C. J. M. |
| المصدر: |
Annals of Hematology ; volume 102, issue 5, page 1203-1213 ; ISSN 0939-5555 1432-0584 |
| بيانات النشر: |
Springer Science and Business Media LLC |
| سنة النشر: |
2023 |
| مصطلحات موضوعية: |
Hematology, General Medicine |
| الوصف: |
Prophylactic donor lymphocyte infusion (DLI) starting at 6 months after T cell-depleted allogeneic stem cell transplantation (TCD-alloSCT) can introduce a graft-versus-leukemia (GvL) effects with low risk of severe graft-versus-host-disease (GvHD). We established a policy to apply low-dose early DLI at 3 months after alloSCT to prevent early relapse. This study analyzes this strategy retrospectively. Of 220 consecutive acute leukemia patients undergoing TCD-alloSCT, 83 were prospectively classified to have a high relapse risk and 43 were scheduled for early DLI. 95% of these patients received freshly harvested DLI within 2 weeks of the planned date. In patients transplanted with reduced intensity conditioning and an unrelated donor, we found an increased cumulative incidence of GvHD between 3 and 6 months after TCD-alloSCT for patients receiving DLI at 3 months compared to patients who did not receive this DLI (0.42 (95%Confidence Interval (95% CI): 0.14–0.70) vs 0). Treatment success was defined as being alive without relapse or need for systemic immunosuppressive GvHD treatment. The five-year treatment success in patients with acute lymphatic leukemia was comparable between high- and non-high-risk disease (0.55 (95% CI: 0.42–0.74) and 0.59 (95% CI: 0.42–0.84)). It remained lower in high-risk acute myeloid leukemia (AML) (0.29 (95% CI: 0.18–0.46)) than in non-high-risk AML (0.47 (95% CI: 0.42–0.84)) due to an increased relapse rate despite early DLI. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1007/s00277-023-05145-1 |
| DOI: |
10.1007/s00277-023-05145-1.pdf |
| DOI: |
10.1007/s00277-023-05145-1/fulltext.html |
| الإتاحة: |
https://doi.org/10.1007/s00277-023-05145-1Test |
| حقوق: |
https://creativecommons.org/licenses/by/4.0Test ; https://creativecommons.org/licenses/by/4.0Test |
| رقم الانضمام: |
edsbas.789BCEE0 |
| قاعدة البيانات: |
BASE |
